SPPI - Spectrum Pharmaceuticals, Inc.
After hours:
Chart Events
Hammer
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.1100 |
| Open | 1.1000 |
| Bid | 1.1000 x 3100 |
| Ask | 1.1100 x 2900 |
| Day's Range | 1.0900 - 1.1200 |
| 52 Week Range | 0.3200 - 1.5700 |
| Volume | |
| Avg. Volume | 2,274,515 |
| Market Cap | 227.841M |
| Beta (5Y Monthly) | 2.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3700 |
| Earnings Date | Aug 09, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Dec 18, 2012 |
| 1y Target Est | 1.26 |
Fair Value
Related Research
Business WireSpectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
BOSTON, May 17, 2023--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) ("Spectrum" or the "Company"), a biopharmaceutical Company focused on novel and targeted oncology announced today that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff (the "Staff") of the Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
Simply Wall St.News Flash: Analysts Just Made A Captivating Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts
Spectrum Pharmaceuticals, Inc. ( NASDAQ:SPPI ) shareholders will have a reason to smile today, with the analysts making...
- Thomson Reuters StreetEvents
Q1 2023 Assertio Holdings Inc Earnings Call
Q1 2023 Assertio Holdings Inc Earnings Call
ZacksSpectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 60% and 27.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireSpectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update
BOSTON, May 09, 2023--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a commercial stage biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2023, and provided a corporate update.
InvestorPlace7 A-Rated Stocks to Buy for May 2023
You’ve undoubtedly heard the adage, “Sell in May and go away.” I’ve never been a fan of that school of thought. While other investors may look to dump their stocks, I think this is an ideal time to look for stocks to buy. Why? First of all, market experts are mixed on the whole issue of “sell in May and go away.” Some experts point to historical data that the market gains an average of only 2% from May to October.InvestorPlace - Stock Market News, Stock Advice & Trading Tips By contrast, the mar
BenzingaAssertio Scoops Up Spectrum Pharma In $248M Stock Deal
Assertio Holdings Inc (NASDAQ: ASRT) will acquire Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) in an all-stock and contingent value rights (CVR) transaction. Under the terms of the agreement, each Spectrum share will be exchanged for a fixed exchange ratio of 0.1783 shares of Assertio common, implying an upfront value of $1.14 per Spectrum share. Additionally, Spectrum stockholders will receive one CVR per Spectrum share, entitling them to receive up to an additional $0.20 per share (approximatel
GlobeNewswireAssertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction
Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams Combination of Assertio’s Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth across All Products Transaction Expected to Be Accretive to Assertio’s Adjusted EPS and Operating Cash Flow in 2024 Spectrum Stockholders Will Receive Upfront Consideration of 0.1783 ASRT shares per SPPI Sh
- Simply Wall St.
Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Trimming Their Forecasts
Spectrum Pharmaceuticals, Inc. ( NASDAQ:SPPI ) defied analyst predictions to release its annual results, which were...
Insider MonkeySpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Q4 2022 Earnings Call Transcript
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Q4 2022 Earnings Call Transcript March 22, 2023 Operator: Good day and thank you for standing by. Welcome to the Spectrum Pharmaceuticals 4Q 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Please be advised that today’s […]
- Thomson Reuters StreetEvents
Q4 2022 Spectrum Pharmaceuticals Inc Earnings Call
Q4 2022 Spectrum Pharmaceuticals Inc Earnings Call
ZacksSpectrum Pharmaceuticals (SPPI) Reports Q4 Loss, Tops Revenue Estimates
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 33.33% and 5.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireSpectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update
BOSTON, March 22, 2023--Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update
Business WireSpectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
BOSTON, March 17, 2023--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2022 financial results and provide a corporate update on Wednesday, March 22, 2023, at 8:30 a.m. Eastern/5:30 a.m. Pacific.
- Business Wire
Spectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON™ (eflapegrastim-xnst) Injection (J1449) from U.S. Centers for Medicare & Medicaid Services
BOSTON, February 08, 2023--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst) Injection by the U.S. Centers for Medicare & Medicaid Services (CMS) effective as of April 1, 2023.
Business WireSpectrum Pharmaceuticals Provides Update on ROLVEDON™ (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial Results
BOSTON, January 31, 2023--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology, today announced business highlights and preliminary ROLVEDON net sales for the quarter and year ended December 31, 2022.
InvestorPlaceThe 3 Best Biotech Stocks Under $1 to Buy for January
While biotech may be the next big thing, making money through it isn’t easy. Indeed, investing in biotech stocks is often more of an art than a science. And considering these companies are solely focused on scientific endeavors, that’s not what many investors want to hear. For every Moderna (NASDAQ:MRNA), which shot to wealth and fame on its MRNA-based COVID vaccine, there’s a CureVac (NASDAQ:CVAC), another MRNA play, down 45% in the last year. Even the biggest biotech stocks, like Eli Lilly (NY
Business WireSpectrum Pharmaceuticals Announces New Employment Inducement Grant for Commercial Staff
BOSTON, January 26, 2023--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that on January 26, 2023, Spectrum’s Board of Directors granted an aggregate of 20,833 inducement restricted stock units ("RSUs") to a commercial non-executive employee who was hired specifically for the launch of ROLVEDON. The award was granted under Spectrum’s 2022 Employment Inducement Incentive Award Plan ("Inducement Plan") as emp
Business WireSpectrum Pharmaceuticals Announces Management Changes
BOSTON, January 04, 2023--Spectrum Pharmaceuticals Announces Management Changes
Business WireSpectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff
BOSTON, December 27, 2022--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that on December 27, 2022, Spectrum’s Board of Directors granted an aggregate of 206,059 inducement restricted stock units ("RSUs") to commercial non-executive employees who were hired specifically for the launch of ROLVEDON. The awards were granted under Spectrum’s 2022 Employment Inducement Incentive Award Plan ("Inducement Plan") a
Business WireSpectrum Pharmaceuticals’ ROLVEDON™ (eflapegrastim-xnst) Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors
BOSTON, December 06, 2022--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that ROLVEDON (eflapegrastim-xnst) has been added to the latest National Comprehensive Cancer Network® Supportive Care Guidelines (NCCN Guidelines) in oncology for Hematopoietic Growth Factors. The NCCN Guidelines provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN) and no
ZacksSpectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA
Spectrum (SPPI) gets a CRL from the FDA for poziotinib as the agency requires additional data. The company de-prioritized the poziotinib program.
BenzingaAfter FDA Rejection, Spectrum Shelves Development On Poziotinib
The FDA has granted a Complete Response Letter (CRL) to Spectrum Pharmaceuticals Inc's (NASDAQ: SPPI) marketing application seeking approval for poziotinib for previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 20 insertion mutations. The FDA issued a CRL indicating that the poziotinib application cannot be approved in its present form. Based on the CRL, the company would have to generate additional data, including a randomized controlled stu
- Reuters
UPDATE 2-U.S. FDA declines to approve Spectrum's lung cancer drug
Spectrum Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration (FDA) declined to approve its experimental lung cancer drug due to inadequate data, prompting the drugmaker to cut jobs. The company said it will no longer focus on developing the drug, poziotinib, for treating non-small cell lung cancer (NSCLC) with a rare genetic mutation that affects 2%-4% of the cancer patients.
Business WireSpectrum Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection
BOSTON, November 25, 2022--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) ("Spectrum" or the "Company"), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Spectrum’s New Drug Application (NDA) for poziotinib for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer ("NSCLC") har